VC: Vitae leads with $15M



Vitae leads with $15 million.

VENTURE CAPITAL

COMPANY

AMOUNT/ROUND

LEAD INVESTORS

DESCRIPTION

Vitae Pharmaceuticals
Fort Washington, PA

$15 million
NA

GlaxoSmithKline

Much of the money will be used to accelerate its multiple programs into the clinic.

Primera Biosystems
Providence, RI

$11 million
first round

MPM Capital, Burrill and Company

The financing will enable Primera to develop both instrument systems and disease specific diagnostic reagent kits for commercialization.

Panacea Pharmaceuticals
Gaithersburg, MD

$7 million
third round

Mitsubishi Corporation Life Sciences Venture

Proceeds from the offering will be used to move potential products within the company's HAAH Oncology Program towards clinical-stage development.

Pepscan Systems
The Netherlands

$6 million
first round

PPM Oost NV

The funds will be used primarily to further expand Pepscan's portfolio of therapeutic vaccines programs in oncology.

Suggested Articles

Avidity Biosciences is on a roll—after inking an R&D deal with Eli Lilly and hiring a new CEO, the company is reeling in $100 million.

What the NASH field needs, says Genfit CEO Pascal Prigent, is something like the Hb1Ac test for diabetes.

Blocking a newly discovered molecule produced by B cells could slow their flow into the brain and offer a new way to treat MS, a Canadian team found.